Targeting the Root of AML: How Myeloid Blast Control Produces Better Outcomes
In AML, the fundamental issue is unchecked proliferation of immature myeloid blasts leading to bone-marrow failure and extramedullary disease. Traditional chemotherapies have limitations in older or frail patients. The introduction of targeted therapy with BCL-2 inhibitors such as venetoclax has shifted the paradigm, allowing deeper remissions and improved tolerability. Here we review how controlling the key malignant cell population addresses the problem, how therapy works, and what results patients can expect in terms of remissio
כמו
תגובה
לַחֲלוֹק
